AstraZeneca’s Naloxegol Meets Primary End Point In Latestage Trial

LONDON dpaAFX AstraZeneca PLC AZN Tuesday said the Phase III study of the investigational drug naloxegol 25 mg met its primary and secondary endpoints and showed a safety profile. Naloxeg...

---

AstraZeneca PLC Release: Results From Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!ORLANDO, Fla.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today presented the results of two pivotal Phase III…

---

AstraZeneca PLC Closes in on Site for New $500 Million Home in Cambridge

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!AstraZeneca is closing in on a site for its new $500 million home in Cambridge, with a biomedical park just s…

---

AstraZeneca PLC Release: Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!AstraZeneca (NYSE: AZN) today presented the results of two pivotal Phase III studies of naloxegol showing the…

---